Bruce Campbell

Bruce Campbell Bsc, PhD Chem FRSC has more than 45 years of drug development experience and has developed 13 drugs or vaccines in a wide range of indications which have made it to the market. Formerly R and D Director at Servier (UK) , Senior VP of Research and Development at Neurocrine Biosciences, Inc (US) , Chief Scientific Officer at IP2IPO ( IPGroup), Founder, Chairman and Head of Development for Proximagen Ltd , he currently acts as a consultant to various pharmaceutical companies in Europe and the USA. In addition, he has been on the board of Proximagen , IPGroup , hVivo, Modern Biosciences, Synairgen and IQur and has been a director and European Chairman of the Drug Information Association, and a member of the European ICH Safety Working Party helping to write ICH safety guidances He is a visiting Professor in Pharmacology at King’s College, London and written more than 100 papers involving all aspects of drug development.